Correction of iron deficiency anaemia using IV CosmoFer in CKD patients with asthma: A prospective study

QJM: An International Journal of Medicine

Volumn 109, Issue 3, 2016, Pages 187-190

  Syed, A ^a   Bhandari, S ^b  

^a BRADFORD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; HEMOGLOBIN; HYDROCORTISONE; IRON DEXTRAN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; ASTHMA; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY ANEMIA; MALE; MEDICAL HISTORY; MIDDLE AGED; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; SINGLE DRUG DOSE; AGED; ANEMIA, IRON-DEFICIENCY; BLOOD; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPLICATION; DRUG ADMINISTRATION; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANEMIA, IRON-DEFICIENCY; ASTHMA; DRUG ADMINISTRATION SCHEDULE; FEMALE; FERRITINS; GLOMERULAR FILTRATION RATE; HEMOGLOBINS; HUMANS; HYDROCORTISONE; INFUSIONS, INTRAVENOUS; IRON-DEXTRAN COMPLEX; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84960332402     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcv117     Document Type: Article

References (29)

1. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002; 162:1401-8.
2. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. AmJ Kidney Dis 2003; 41:1-12.
3. James JD. Diagnosis and management of iron-deficiency anaemia. Best Pract Res Clin Haematol 2005; 18:319-32.
4. Bhandari S. Iron therapy in patients with chronic kidney disease. iron therapy in clinical practice: an overview. Transfus Altern Transfus Med 2012; 12:115-21.
5. Bhandari S. Oral iron properties and current place in the treatment of anaemia. Prescriber 2012; 6:12-8.
6. Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ 2013; 347:f4822.
7. Bhandari S and Naudeer S. Improving efficiency and value in health care. Intravenous iron management for anaemia associated with chronic kidney disease. Linking treatment to an outpatient clinic, optimising service provision and patient choice. J Eval Clin Pract 2008; 14:996-1001.
8. McCarthy JT, Regnier CE, Loebertmann CL, Bergstralh EJ. Adverse events in chronic haemodialysis patients receiving intravenous iron dextran-a comparison of two products. Am J Nephrol 2000; 20:455-62.
9. Moniem KA, Bhandari S. Tolerability and efficacy of parenteral iron therapy in haemodialysis patients a comparison of two preparations. Transfus Altern Transfus Med 2007; 9:37-42.
10. Cooke M, Lamplugh A, Naudeer S, Eddy M, Bhandari S. Efficacy and tolerability of accelerated-dose low-molecularweight iron dextran (Cosmofer) in patients with chronic kidney disease. Am J Nephrol 2012; 35:69-74.
11. Fletes R, Lazarus JM, Gage J, Chertow GM. Suspected iron dextran-related adverse drug events in haemodialysis patients. Am J Kidney Dis 2001; 37:743-9.
12. The Global Asthma Report 2014. Global Asthma Network, http://www.globalasthmareport.org/index.php (1 July 2015, date last accessed).
13. Quality and Outcomes Framework-Prevalence, Achievements and Exceptions Report, England 2013-14. Health and social care information centre, U.K. http://www.hscic.gov.uk/catalogue/PUB15751/qof-1314-report.pdf (1 July 2015, date last accessed).
14. Wysowski DK, Swartz L, Borders-Hemphill BV, Goulding MR, Dormitzer C. Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol 2010; 85:650-4.
15. Cherlow GM, Winkelmayer WC. Commentary: on the relative safety of intravenous iron formulations. New answers, new questions. Am J Hematol 2010; 85:643-4.
16. European Medicines Agency. New Recommendations to Manage Risk of Allergic Reactions with Intravenous Iron-Containing Medicines. European Medicines Agency 2013. EMA/579491/2013:1-3. http://www.ema.europa.eu/docs/en_GB/document_ library/Referrals_document/IV _iron_31/WC500151308.pdf (6 July 2015, date last accessed).
17. British Thoracic Society and Scottish Intercollegiate Guidelines Network (SIGN). British Guideline on the Management of Asthma. A National Clinical Guideline. (SIGN publication no.101). http://www.sign.ac.uk/guidelines/fulltext/101/index. html (6 July 2015, date last accessed).
18. Thomas M, Gruffydd-Jones K, Stonham C, Ward S, Macfarlane TV. Assessing asthma control in routine clinical practice: use of the Royal College of Physicians '3questions'. Prim Care Respir J 2009; 18:83-8.
19. Ekmekci OB, Donma O, Sardoğan E, Yildirim N, Uysal O, Demirel H, et al. Iron, nitric oxide, and myeloperoxidase in asthmatic patients. Biochemistry 2004; 69:462-7.
20. Wu Z, Holwill SD, Oliveira DB. Desferrioxamine modulates chemically induced T helper 2-mediated autoimmunity in the rat. Clin Exp Immunol 2004; 135:194-9.
21. Maazi H, Shirinbak S, Bloksma N, Nawijn MC, van Oosterhout AJM. Iron administration reduces airway hyperreactivity and eosinophilia in a mouse model of allergic asthma. Clin Exp Immunol 2011; 166:80-6.
22. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21:378-82.
23. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 2005; 216:106-21.
24. Szebeni J. Hemocompatibility testing for nanomedicines and biologicals: predictive assays for complement mediated infusion reactions. Eur J Nanomed 2012; 1:33-53.
25. Critchley J, Dunbar Y. Adverse events associated with intravenous iron infusion (low-molecular-weight iron dextran and iron sucrose): a systematic review. Transfus Altern Transfus Med 2007; 9:8-36.
26. Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V, Wish J. The safety of intravenous iron dextran in haemodialysis patients. Am J Kidney Dis 1996; 28:529-34.
27. Hetzel D, StraussW, Bernard K, Li Z, Urboniene A, Allen LF. A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. Am J Hematol 2014; 896:646-50.
28. Goss JE, Chambers CE, Heupler FA Jr. Systemic anaphylactoid reactions to iodinated contrast media during cardiac catheterization procedures: guidelines for prevention, diagnosis, and treatment. Laboratory Performance Standards Committee of the Society for Cardiac Angiography and Interventions. Cathet Cardiovasc Diagn 1995; 34:99-104.
29. Tramèr MR, von Elm E, Loubeyre P, Hauser C. Pharmacological prevention of serious anaphylactic reactions due to iodinated contrast media: systematic review. BMJ 2006; 333:675.